Stosic-Grujicic, S. (7004253020)S. (7004253020)Stosic-GrujicicOstojic, N. (6701663928)N. (6701663928)OstojicLukic, M.L. (7005792112)M.L. (7005792112)Lukic2025-06-122025-06-121994https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028557299&partnerID=40&md5=adf3baa19d36a61a9e9c90fe7551b6achttps://remedy.med.bg.ac.rs/handle/123456789/1686To investigate the role of IL-1 in nitric oxide (NO)-mediated destructive processes in the multiple low dose streptozotocin (MLD-STZ) induced model of autoimmune diabetes, CBA/H mice received 10 consecutive i.p. injections of either rat IL-1 inhibitor (IL-1 INH), or human recombinant IL-1 receptor antagonist (IL-1ra). In contrast to the control MLD-STZ group (40-45 mg/kg for 5 days) which developed persistent hyperglycemia associated with insulitis and islet cell destruction, both IL-1 INH- and rIL-1ra-treated mice were protected from the induction of the disease. Preliminary immunohistochemical studies indicated that the high local concentration of NO-producing enzyme NO synthase, present in control MLD-STZ islets, is significantly reduced in both experimental groups of mice where IL-1 activity was blocked either by IL-1 INH or rIL-1ra.Autoimmune diseasesDiabetes mellitusInterleukin-1